All In Biotech

Drug Trial Radar · NCT03713905

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of the Recombinant Human Anti-PD-1 Monoclonal Antibody for Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

293

Actual

Start

Jul 1, 2017

Primary completion

Feb 28, 2022

Study completion Feb 28, 2022

Sponsor

Sponsor type
Industry
First posted
Oct 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the safety and tolerability of GLS-010 in subjects with advanced solid tumors (mainly gastric cancer, esophageal cancer). To investigate the preliminary relationship between the expression of the ligand of PD-1 (PD-L1) and efficacy.

Conditions

  • Advanced Solid Tumors

Interventions

  • GLS-010Drug

    Recombinant Human Anti-PD-1 Monoclonal Antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of GLS-010 by assessing the percentage of participants who experience a dose-limiting toxicity (DLT)Time frame: 28 days after patient enrolled

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital & Institute

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.